Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01342224 · ClinicalTrials.gov registry record · Phase 1
Immunochemoradiotherapy in Patients With Pancreatic Cancer
A Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01342224 is a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma that has completed, run by Providence Health & Services. The registered enrollment target is 11 participants, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01342224, a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger study is warranted.
Conditions Studied
Interventions
- BIOLOGICAL tadalafil and vaccination
Study Locations (1)
Oregon
- Providence Health & Services - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-01 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01342224
The ClinicalTrials.gov registry entry for NCT01342224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (83% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which tadalafil and vaccination is the first listed.
NCT01342224 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT01342224 about?
NCT01342224 is a clinical study titled "Immunochemoradiotherapy in Patients With Pancreatic Cancer". This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger study is warranted.
What is the current status of trial NCT01342224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-01. Estimated completion is 2018-04.
What conditions does trial NCT01342224 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT01342224?
The interventions under investigation include: tadalafil and vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT01342224?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01342224 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
BATs Treatment for Pancreatic Cancer, Phase Ib/II
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.